Table 2.
Characteristics of the patients who were included (LDL cholesterol <3.35 mmol/L) or not (LDL cholesterol ≥3.35 mmol/L) in the study
| Included patients n = 1080 |
Excluded patients n = 543 |
p | |
|---|---|---|---|
| Clinical characteristics | |||
| Age, years | 61.6 ± 9.0 | 60.3 ± 9.2 | 0.09 |
| Gender, male/female | 614/466 | 291/252 | 0.21 |
| Body mass index, kg/m2 | 30.2 ± 5.9 | 30.3 ± 6.4 | 0.786 |
| Diabetes | |||
| Diabetes duration, years | 13.8 ± 8.5 | 13.7 ± 3.7 | 0.838 |
| HbA1c, % | 8.5 ± 1.8 | 8.9 ± 2.5 | <0.001 |
| Retinopathy, % | 357 (34.2) | 180 (34.0) | 0.94 |
| Nephropathy, % | 406 (57.3) | 181 (30.8) | <0.001 |
| Peripheral neuropathy, % | 233 (13.9) | 139 (45.4) | 0.71 |
| Peripheral arterial occlusive disease, % | 119 (11.3) | 56 (10.4) | 0.58 |
| Family history of premature CAD, % | 137 (13.0) | 69 (13.4) | 0.83 |
| Additional cardiovascular risk factors | |||
| Hypertension, % | 402 (76.3) | 235 (72.8) | 0.25 |
| Dyslipidemia, % | 244 (65.3) | 246 (72.1) | <0.01 |
| Lipid parameters | |||
| HDL cholesterol, mmol/L | 1.3 ± 0.5 | 1.2 ± 0.4 | 0.001 |
| Triglycerides, mmol/L | 1.7 ± 1.0 | 1.9 ± 1.0 | <0.001 |
| LDL cholesterol, mmol/L | 2.4 ± 0.6 | 4.1 ± 0.7 | <0.001 |
| Non-HDL cholesterol, mmol/L | 3.2 ± 0.7 | 4.9 ± 0.9 | <0.0001 |
| Apoprotein A1, g/L | 1.47 ± 0.29 | 1.50 ± 0.30 | 0.506 |
| Apoprotein B, g/L | 0.89 ± 0.18 | 1.31 ± 0.23 | <0.0001 |
| Fibrate treatment, % | 96 (9.1) | 61 (11.8) | 0.085 |
| Statin treatment, % | 438 (41.4) | 129 (25.0) | <0.001 |
| Smoking, % | 245 (22.8) | 135 (25.1) | 0.30 |
CAD coronary artery disease